Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite)

• Published in: Scientific reports Vol. 7; no. 1; pp. 17190 - 11
• Main Authors: Chen, Wenge, Xiao, Yingying, Chen, Jianzhong, Liu, Jian, Shao, Jingwei, Li, Tao, Zhu, Yewei, Ma, Ji, Gao, Yu, Wang, Jichuang, Xu, Jianguo, Lu, Yusheng, Jia, Lee
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.12.2017; Nature Publishing Group
• Subjects: 631/67/1059/99; 64/60; 692/699/67/1059/153; 9/10; Cancer; CYP1A2 protein; Cytochrome P450; Humanities and Social Sciences; Kidneys; Liver; Metabolites; Metastases; Microsomes; Mifepristone; multidisciplinary; Oral administration; Pharmacokinetics; Phenotyping; Rodents; Science; Science (multidisciplinary); Sex differences
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-17225-0

Metapristone is the primary metabolite of the abortifacient mifepristone (RU486), and is being developed as a safe and effective cancer metastatic chemopreventive agent for both sexes. Here, we systematically investigated the sex-related pharmacokinetics of metapristone in both rats and dogs, and explored the related mechanisms of actions. Administration of metapristone to rats and dogs showed that plasma concentrations of metapristone ( AUC , C max ) were significantly higher in female dogs and rats than in males. The sex-related differences in pharmacokinetics become more significant after ten consecutive days of oral administration. Female liver microsomes metabolized metapristone significantly slower than the male ones. The results from P450 reaction phenotyping using recombinant cDNA-expressed human CYPs in conjunction with specific CYP inhibitors suggested that CYP1A2 and CYP3A4 are the predominant CYPs involved in the metapristone metabolism, which were further confirmed by the enhanced protein levels of CYP1A2 and CYP3A4 induced by 1-week oral administration of metapristone to rats. The highest tissue concentration of metapristone was found in the liver. The study demonstrates, for the first time, the sex-related pharmacokinetics of metapristone, and reveals that activities of liver microsomal CYP1A2 and CYP3A4 as well as the renal clearance are primarily responsible for the sex-related pharmacokinetics.